Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 10, 2015, Pages 2810-2815

  Osman, Nathan ^a,b   Mesplede, Thibault ^a   Quashie, Peter K ^a,b   Oliveira, Maureen ^a   Zanichelli, Veronica ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DOLUTEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; LYSINE; MK 2048; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS;

AMINO ACID SUBSTITUTION; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; ENZYME ACTIVITY; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; INCUBATION TIME; NONHUMAN; OPEN READING FRAME; TISSUE CULTURE; TISSUE WATER; VIRUS LOAD; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIAL SENSITIVITY TEST; MUTATION; PHYSIOLOGY; T LYMPHOCYTE; VIROLOGY;

CELL LINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; T-LYMPHOCYTES; VIRUS REPLICATION;

EID: 84943792977     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv176     Document Type: Article

References (21)

1. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369: 1261-9.
2. Shimura K, Kodama E, Sakagami Y et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82: 764-74.
3. Delelis O, Thierry S, Subra F et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 2010; 54: 491-501.
4. Maiga AI, Malet I, Soulie C et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther 2009; 14: 123-9.
5. Kobayashi M, Yoshinaga T, Seki Tet al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55: 813-21.
6. Lenz JC, Rockstroh JK. S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges. Expert Opin Investig Drugs 2011; 20: 537-48.
7. Prada N, Markowitz M. Novel integrase inhibitors for HIV. Expert Opin Investig Drugs 2010; 19: 1087-98.
8. Quashie PK, Mesplede T, Han YS et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86: 2696-705.
9. Mesplede T, Quashie PK, Osman N et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013; 10: 22.
10. Mesplede T, Osman N, WaresM et al. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 2014; 69: 2733-40.
11. Wares M, Mesplede T, Quashie PK et al. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 2014; 11: 7.
12. Oliveira M, Mesplède T, Quashie PK et al. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014; 28: 813-9.
13. Mesplède T, Moïsi D, Oliveira M et al. Dolutegravir inhibits HIV-1 Env evolution in primary human cells. AIDS 2015; 29: 659-65.
14. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8.
15. Eron JJ, Clotet B, Durant J et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207: 740-8.
16. RaffiF, Rachlis A, Stellbrink HJ et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381: 735-43.
17. Molina JM, Clotet B, van Lunzen J et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc 2014; 17: 19490.
18. Hightower KE, Wang R, Deanda F et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011; 55: 4552-9.
19. Johnson VA, Byington RE. Infectivity assay (virus yield assay). In: Aldovini A, Walker BD, eds. Techniques in HIV Research. New York: Stockton Press, 1990; 71-6.
20. Quan Y, Brenner BG, Marlink RG et al. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses 2003; 19: 743-53.
21. Thierry S, Munir S, Thierry E et al. Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 DNA initiate de novo integration. Retrovirology 2015; 12: 24.